|Type||French Société anonyme corporation with board of directors|
|Industry||Biotechnology, genome engineering|
|Headquarters||Paris XIIIème and Évry (France), Gothenburg (Sweden), New Brighton (Minnesota) and Cambridge (Massachusetts) United States|
|Key people||André Choulika, David Sourdive|
|Products||Nucleases : TALEN™, meganuclease|
|Revenue||21M€ as of Dec, 2012|
|Employees||228 as of December 31, 2012|
Founded in 1999, Cellectis is a biotech group based on a genome engineering technology. Cellectis is able to alter the DNA of any living organism in very precise ways so as to modify, delete, or replace all or part of a gene. The applications of this are numerous: fighting specific diseases to designing innovative biopharmaceuticals, the invention of new plant species, regenerative medicine, development of bio-energies…
The Cellectis Group is organized with several subsidiaries dedicated to different target markets to develop totally new treatments for diabetes and cancer, provide break-through research solutions to scientists the world over, and design highly innovative crop varieties. Cellectis specializes in pluripotent stem cells. We have developed special expertise in drug discovery and toxicity testing as well as regenerative medicine. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.
Established in 2008, Cellectis therapeutics develops innovative processes employing the Group’s proprietary tools —nucleases and cell lines— to treat certain cancers, metabolic disorders such as diabetes, and persistent viral infections.
This biopharmaceuticals unit is organized around two specific approaches:
- adoptive cell transfer immunotherapy, using T-cells engineered to fight tumors and viruses.
Cellectis plant sciences
Established in March 2010, the Group’s subsidiary Cellectis plant sciences develops protocols for engineering agronomic traits to create new plant varieties. Based in New Brighton, Minnesota (United States). Cellectis plant sciences has developed a reliable gene disruption technique, able to suppress the expression of one or more target genes in order to engineer new traits.
Established in 2008, Cellectis bioresearch combines its expertise in targeted DNA editing and stem cell technology to develop tools and services for the life sciences industry. With operations in the United States, Sweden, and France (Paris and Évry), Cellectis bioresearch offers its clients a comprehensive set of solutions and a broad range of products and services for all types of projects in the technologies of genome, protein, and cell engineering.
On July 8, 2013 the Cellectis Group announced that it was launching Scéil™, the first ever service enabling members of the general public to store induced pluripotent stem cells (iPS), processed from samples of their own skin, for possible future use as new regenerative medicine techniques become available. The program’s availability in various geographic regions is subject to prevailing laws and regulations. Scéil™ is not available in France.
André Choulika, PhD is the Chairman, CEO, and co-founder of Cellectis. Dr Choulika is a pioneer in the analysis and use of meganucleases to modify complex genomes. After receiving his doctorate in molecular virology from Pierre-and-Marie-Curie University of Paris VI, he completed a research fellowship in the Harvard Medical School Department of Genetics. Later, while working in the Division of Molecular Medicine at Boston Children’s Hospital, he developed the first approaches to meganuclease-based human gene therapy. Dr Choulika also has management training from the HEC Paris (Challenge +). André Choulika is also the Chairman of France Biotech since June 2009.
The Executive Committee
- André Choulika, Chairman and Chief Executive Officer
- David Sourdive, Executive Vice President of Corporate Development
- Mathieu Simon, Senior Vice President
- Xavier Champavère, Deputy Chief Executive Officer of Cellectis bioresearch
- Jean-Charles Epinat, Deputy Chief Executive Officer of Cellectis bioresearch
- Luc Mathis, Chief Executive Officer of Cellectis plant sciences
- Philippe Duchateau, Chief Scientific Officer
- Pierre Schwich, Chief Financial Officer
- Philippe Valachs, Company Secretary
The Board of Directors
- André Choulika, Chairman and Chief Executive Officer
- David Sourdive, Director, Executive Vice President of Corporate Development
- Alain Godard, Independent director
- Kaminvest, Director, Represented by Roger J. Hajjar
- Pierre Bastid, Director
- Laurent Arthaud, Director
- Annick Schwebig, Director
- Institut Pasteur, Non-voting Director, Represented by Pascale Augé
The Scientific Advisory Board
- Professor Rodney J. Rothstein, Chairman of the Scientific Advisory Board, PhD, Columbia University, New York City, USA
- Professor Frederick W. Alt, PhD, Howard Hughes Medical Institute, Chevy Chase, Maryland, USA; Harvard Medical School, Boston, USA
- Professor Bernard Dujon, PhD, Pierre-and-Marie-Curie University (Paris VI), Institut Pasteur, Paris, France
- Professor Alain Fischer, MD, PhD, Necker Children's Hospital, Paris, France
- Professor James E. Haber, PhD, Brandeis University, Waltham, Massachusetts, USA
- Professor Denis Pompon, PhD, Centre de génétique moléculaire, CNRS, Gif-sur-Yvette, France
- Professor Luis Serrano, PhD, Center for Genomic Regulation (C.R.G.), Barcelona, Spain
- Doctor Frédéric Pâques, PhD, École Normale Supérieure, Former Chief Scientific Officer of Cellectis, France
Find all scientific publications on Cellectis' website